This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Shire Buying Viropharma for $4.2B to Bolster Rare Disease Unit

Shire (SHPG - Get Report) is buying Viropharma Pharmaceuticals (VPHM) for $4.2 billion to bolster its portfolio of drugs treating rare diseases, the companies announced Monday.

The all-cash deal values Viropharma at $50 per share, or a 27% premium to the company's closing stock price Friday. 

Viropharma's best-selling product is Cinryze, which treats hereditary angioedema, a rare blood disease that causes swelling. Viropharma sales totaled $428 million last year, the bulk coming from Cinryze. The company is expected to generated $445-$465 million in sales this year. 

"By joining with Shire, ViroPharma will become part of a larger, more diverse biopharmaceutical company and will benefit from Shire's innovation, scale and global reach," said Viropharma CEO Vincent Milano, in a statement.

Must Read: FDA Slaps Aegerion CEO For 'Serious' Violations of Drug Promotion Law

Shire intends to fold Viropharma into its business unit that sells drugs for rare diseases. These include Finryze, which also targets hereditary angioedema, as well as drugs for Gaucher and Fabry disease. 

Once the Viropharma acquisition closes, Shire expects its rare disease unit to generate $2 billion in revenue in 2014, or 40% of its total revenue on a pro forma basis.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
VPHM $49.96 -0.02%
SHPG $180.81 -3.00%
AAPL $95.04 -0.15%
FB $117.33 -0.08%
GOOG $694.12 0.25%


Chart of I:DJI
DOW 17,718.82 -32.09 -0.18%
S&P 500 2,054.49 -8.88 -0.43%
NASDAQ 4,744.7920 -18.4320 -0.39%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs